HK Stock Market Move | HAO TIAN INT'L (01341) rose more than 6% in early trading, completing the issuance and distribution of 1.6 billion shares of consideration shares to PCL.
Hao Tian International Construction Investment (01341) rose more than 6% in the morning session. As of the time of writing, it had risen by 5.61% to HK$0.226, with a trading volume of HK$28.022 million.
HAO TIAN INTL (01341) rose more than 6% in early trading, with a 5.61% increase at the time of writing, reaching 0.226 Hong Kong dollars, with a turnover of 28.022 million Hong Kong dollars.
On the news front, on October 22, HAO TIAN INTL announced that all conditions set out in the subscription agreement had been reached on October 17, 2025, and the completion was carried out in accordance with the terms and conditions of the subscription agreement on October 22, 2025. According to the subscription agreement, PCL has issued and subscribed for shares in the company, accounting for approximately 29.82% of the total number of PCL shares enlarged by the subscription shares, while the company has issued and placed 1.6 billion shares of consideration shares to PCL, accounting for approximately 14.75% of the total number of shares enlarged by the consideration shares.
It is reported that PLANETREE INT'L had previously announced that its wholly-owned subsidiary PCL issued 850 new shares to HAO TIAN INTL at a price of 400 million Hong Kong dollars, which HAO TIAN INTL will pay for by issuing 1.6 billion consideration shares. After completion, the company will hold 14.8% of HAO TIAN INTL's share capital, becoming its main shareholder; the company's stake in PCL will be diluted from 100% to 70.2%, making it a licensed company regulated by the Securities and Futures Commission.
Related Articles

withdraw liquidation application
.png)
Subsidiary of GIANT BIOGENE (02367) received the "Medical Device Registration Certificate of the People's Republic of China" for the recombined Type I 1 subtype collagen freeze-dried fiber product.

WASION HOLDINGS (03393): Willfar Information Technology's net profit attributable to shareholders for the first three quarters increased by 12.24% year-on-year to 474 million yuan.
withdraw liquidation application

Subsidiary of GIANT BIOGENE (02367) received the "Medical Device Registration Certificate of the People's Republic of China" for the recombined Type I 1 subtype collagen freeze-dried fiber product.
.png)
WASION HOLDINGS (03393): Willfar Information Technology's net profit attributable to shareholders for the first three quarters increased by 12.24% year-on-year to 474 million yuan.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025